Astrana Health (NASDAQ:ASTH) Rating Increased to Hold at Macquarie

Astrana Health (NASDAQ:ASTH) was upgraded by research analysts at Macquarie to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Several other brokerages have also issued reports on ASTH. Robert W. Baird increased their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. BTIG Research increased their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. TD Cowen initiated coverage on Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 price objective for the company. Finally, KeyCorp began coverage on shares of Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $65.17.

Astrana Health Stock Performance

NASDAQ:ASTH opened at $35.52 on Monday. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The firm’s fifty day simple moving average is $49.04 and its 200 day simple moving average is $48.12. The stock has a market cap of $2.00 billion, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 1.80 and a beta of 1.13. Astrana Health has a twelve month low of $34.11 and a twelve month high of $63.20.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. During the same quarter in the previous year, the firm posted $0.47 EPS. As a group, research analysts predict that Astrana Health will post 1.16 EPS for the current year.

Hedge Funds Weigh In On Astrana Health

Several large investors have recently modified their holdings of ASTH. Central Pacific Bank Trust Division bought a new stake in Astrana Health during the 3rd quarter valued at about $160,000. SG Americas Securities LLC purchased a new stake in shares of Astrana Health during the third quarter valued at approximately $680,000. Granite Bay Wealth Management LLC bought a new stake in shares of Astrana Health during the third quarter valued at approximately $290,000. Handelsbanken Fonder AB purchased a new position in Astrana Health in the 3rd quarter worth approximately $492,000. Finally, GAMMA Investing LLC bought a new position in Astrana Health in the 3rd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.